🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11685744

CDK inhibitors and their use as pharmaceuticals

Prelude Therapeutics, Incorporated · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11685749

C26-linked rapamycin analogs as mTOR inhibitors

Revolution Medicines, Inc. · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11685775

Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by adm

The Regents of the University of California · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679112

Cancer treatments using combinations of CDK and ERK inhibitors

Biomed Valley Discoveries, Inc. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679101

Anhydrous compositions of mTOR inhibitors and methods of use

PALVELLA THERAPEUTICS, INC. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11673898

Substituted inhibitors of menin-MLL and methods of use

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11673896

Pyridine compounds as allosteric SHP2 inhibitors

Revolution Medicines, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11673893

CDK inhibitors and their use as pharmaceuticals

Prelude Therapeutics, Incorporated · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672791

Tyrosine kinase inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672793

Compositions of CXCR4 inhibitors and methods of preparation and use

X4 Pharmaceuticals, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672774

Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11666645

CD200 inhibitors and methods of use thereof

Regents of the University of Minnesota · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11667637

Fused imidazo-piperidine JAK inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11667643

RIP1K inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11666606

Methods of treating joint disease, disorders and conditions with tissue inhibitors of matr

Prime Merger Sub, LLC · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11661401

2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allost

Revolution Medicines, Inc. · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11661426

Imidazole-containing inhibitors of ALK2 kinase

BioCryst Pharmaceuticals, Inc. · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11655248

Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor

Medshine Discovery Inc. · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654142

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654157

Methods and compositions for cancer therapies that include delivery of halogenated thymidi

Shuttle Pharmaceuticals, Inc. · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654147

ALK2 inhibitors and methods for inhibiting BMP signaling

The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649261

Crystalline forms of a CD73 inhibitor and uses thereof

Arcus Biosciences, Inc. · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649218

C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649251

Substituted inhibitors of menin-MLL and methods of use

Kura Oncology, Inc. · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted